I propose to take Questions Nos. 1603 and 1634 together.
I am aware of the concerns raised by the Irish Haemochromatosis Association and I agree that a model of care needs to be established for haemochromatosis patients that would provide equal access in the most cost-effective manner possible. In this regard the HSE's National Clinical Programme for Blood Transfusion has reviewed services nationally for haemochromatosis patients with a view to providing a service that reflects best international practice in terms of patient care and value for money. I understand that discussions are ongoing with all relevant parties to implement a solution for haemochromatosis services and I look forward to hearing the outcome. There are no plans to extend the list of conditions covered by the Long Term Illness Scheme.
Under the Drug Payment Scheme, no individual or family pays more than €132 per calendar month towards the cost of approved prescribed medicines. The scheme significantly reduces the cost burden for families and individuals incurring ongoing expenditure on medicines. In addition, people who cannot, without undue hardship, arrange for the provision of medical services for themselves and their dependants may be entitled to a medical card. In the assessment process, the Health Service Executive can take into account medical costs incurred by an individual or a family. Those who are not eligible for a medical card may still be able to avail of a GP visit card, which covers the cost of general practice consultation.
